190 related articles for article (PubMed ID: 34908192)
1. Worst itch numerical rating scale for prurigo nodularis: a psychometric evaluation.
Ständer S; Zeidler C; Pereira M; Szepietowski JC; McLeod L; Qin S; Williams N; Sciascia T; Augustin M
J Eur Acad Dermatol Venereol; 2022 Apr; 36(4):573-581. PubMed ID: 34908192
[TBL] [Abstract][Full Text] [Related]
2. Validation of Psychometric Properties of the Itch Numeric Rating Scale for Pruritus Associated With Prurigo Nodularis: A Secondary Analysis of a Randomized Clinical Trial.
Kimel M; Zeidler C; Kwon P; Revicki D; Ständer S
JAMA Dermatol; 2020 Dec; 156(12):1354-1358. PubMed ID: 32936233
[TBL] [Abstract][Full Text] [Related]
3. Worst Itch Numeric Rating Scale for Prurigo Nodularis: A Secondary Analysis of 2 Randomized Clinical Trials.
Kwatra SG; Yosipovitch G; Kim B; Stander S; Rhoten S; Ivanescu C; Haeusler N; Brookes E; Msihid J; Makhija M; Bansal A; Thomas RB; Bahloul D
JAMA Dermatol; 2024 Jun; ():. PubMed ID: 38865146
[TBL] [Abstract][Full Text] [Related]
4. Validation of the Peak Pruritus Numerical Rating Scale as a Patient-Reported Outcome Measure in Prurigo Nodularis.
Kwatra SG; Rodriguez D; Dias-Barbosa C; Budhiarso I; Fofana F; Vernon M; Gabriel S; Piketty C; Puelles J
Dermatol Ther (Heidelb); 2023 Oct; 13(10):2403-2416. PubMed ID: 37615836
[TBL] [Abstract][Full Text] [Related]
5. Psychometric validation and meaningful change thresholds of the Worst Itching Intensity Numerical Rating Scale for assessing itch in patients with chronic kidney disease-associated pruritus.
Vernon MK; Swett LL; Speck RM; Munera C; Spencer RH; Wen W; Menzaghi F
J Patient Rep Outcomes; 2021 Dec; 5(1):134. PubMed ID: 34952964
[TBL] [Abstract][Full Text] [Related]
6. The Sleep Disturbance Numerical Rating Scale: Content Validity, Psychometric Validation, and Meaningful Within-Patient Change in Prurigo Nodularis.
Ständer S; Fofana F; Dias-Barbosa C; Rodriguez D; Budhiarso I; Jabbar-Lopez ZK; Piketty C; Vernon M; Puelles J
Dermatol Ther (Heidelb); 2023 Jul; 13(7):1587-1602. PubMed ID: 37329468
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of vixarelimab, a human monoclonal oncostatin M receptor β antibody, in moderate-to-severe prurigo nodularis: a randomised, double-blind, placebo-controlled, phase 2a study.
Sofen H; Bissonnette R; Yosipovitch G; Silverberg JI; Tyring S; Loo WJ; Zook M; Lee M; Zou L; Jiang GL; Paolini JF
EClinicalMedicine; 2023 Mar; 57():101826. PubMed ID: 36816342
[TBL] [Abstract][Full Text] [Related]
8. A population pharmacokinetic-pharmacodynamic model evaluating efficacy of nalbuphine extended-release in patients with prurigo nodularis.
Eudy-Byrne R; Riggs M; Hawi A; Sciascia T; Rohatagi S
Br J Clin Pharmacol; 2023 Jul; 89(7):2088-2101. PubMed ID: 36680419
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of oral nalbuphine extended release in prurigo nodularis: results of a phase 2 randomized controlled trial with an open-label extension phase.
Weisshaar E; Szepietowski JC; Bernhard JD; Hait H; Legat FJ; Nattkemper L; Reich A; Sadoghi B; Sciascia TR; Zeidler C; Yosipovitch G; Ständer S
J Eur Acad Dermatol Venereol; 2022 Mar; 36(3):453-461. PubMed ID: 34780095
[TBL] [Abstract][Full Text] [Related]
10. Psychometric properties of the Itch Numeric Rating Scale in patients with moderate-to-severe plaque psoriasis.
Kimball AB; Naegeli AN; Edson-Heredia E; Lin CY; Gaich C; Nikaï E; Wyrwich K; Yosipovitch G
Br J Dermatol; 2016 Jul; 175(1):157-62. PubMed ID: 26852717
[TBL] [Abstract][Full Text] [Related]
11. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis.
Yosipovitch G; Reaney M; Mastey V; Eckert L; Abbé A; Nelson L; Clark M; Williams N; Chen Z; Ardeleanu M; Akinlade B; Graham NMH; Pirozzi G; Staudinger H; Plaum S; Radin A; Gadkari A
Br J Dermatol; 2019 Oct; 181(4):761-769. PubMed ID: 30729499
[TBL] [Abstract][Full Text] [Related]
12. Psychometric properties of the itch numeric rating scale, skin pain numeric rating scale, and atopic dermatitis sleep scale in adult patients with moderate-to-severe atopic dermatitis.
Silverberg JI; DeLozier A; Sun L; Thyssen JP; Kim B; Yosipovitch G; Nunes FP; Gugiu PC; Doll HA; Eichenfield LF
Health Qual Life Outcomes; 2021 Oct; 19(1):247. PubMed ID: 34688290
[TBL] [Abstract][Full Text] [Related]
13. Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.
Ständer S; Yosipovitch G; Legat FJ; Lacour JP; Paul C; Narbutt J; Bieber T; Misery L; Wollenberg A; Reich A; Ahmad F; Piketty C
N Engl J Med; 2020 Feb; 382(8):706-716. PubMed ID: 32074418
[TBL] [Abstract][Full Text] [Related]
14. Measurement properties of the Patient-Reported Outcomes Information System (PROMIS
Silverberg JI; Lai JS; Patel KR; Singam V; Vakharia PP; Chopra R; Sacotte R; Kantor R; Hsu DY; Cella D
Br J Dermatol; 2020 Nov; 183(5):891-898. PubMed ID: 32107772
[TBL] [Abstract][Full Text] [Related]
15. Dupilumab in patients with prurigo nodularis: two randomized, double-blind, placebo-controlled phase 3 trials.
Yosipovitch G; Mollanazar N; Ständer S; Kwatra SG; Kim BS; Laws E; Mannent LP; Amin N; Akinlade B; Staudinger HW; Patel N; Yancopoulos GD; Weinreich DM; Wang S; Shi G; Bansal A; O'Malley JT
Nat Med; 2023 May; 29(5):1180-1190. PubMed ID: 37142763
[TBL] [Abstract][Full Text] [Related]
16. Assessing Itch Severity: Content Validity and Psychometric Properties of a Patient-Reported Pruritus Numeric Rating Scale in Atopic Dermatitis.
Rams A; Baldasaro J; Bunod L; Delbecque L; Strzok S; Meunier J; ElMaraghy H; Sun L; Pierce E
Adv Ther; 2024 Apr; 41(4):1512-1525. PubMed ID: 38363461
[TBL] [Abstract][Full Text] [Related]
17. Dupilumab in prurigo nodularis: a systematic review of current evidence and analysis of predictive factors to response.
Husein-ElAhmed H; Steinhoff M
J Dermatolog Treat; 2022 May; 33(3):1547-1553. PubMed ID: 33200955
[TBL] [Abstract][Full Text] [Related]
18. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis.
Kwatra SG; Yosipovitch G; Legat FJ; Reich A; Paul C; Simon D; Naldi L; Lynde C; De Bruin-Weller MS; Nahm WK; Sauder M; Gharib R; Barbarot S; Szepietowski JC; Conrad C; Fleischer A; Laquer VT; Misery L; Serra-Baldrich E; Lapeere H; Ahmad F; Jabbar Lopez ZK; Piketty C; Ständer S;
N Engl J Med; 2023 Oct; 389(17):1579-1589. PubMed ID: 37888917
[TBL] [Abstract][Full Text] [Related]
19. A Phase 3 Trial of Difelikefalin in Hemodialysis Patients with Pruritus.
Fishbane S; Jamal A; Munera C; Wen W; Menzaghi F;
N Engl J Med; 2020 Jan; 382(3):222-232. PubMed ID: 31702883
[TBL] [Abstract][Full Text] [Related]
20. Effect of Roflumilast Cream (ARQ-151) on Itch and Itch-Related Sleep Loss in Adults with Chronic Plaque Psoriasis: Patient-Reported Itch Outcomes of a Phase 2b Trial.
Stein Gold L; Alonso-Llamazares J; Draelos ZD; Gooderham MJ; Kempers SE; Kircik LH; Lebwohl MG; Papp KA; Pariser DM; Toth DP; Yosipovitch G; Higham RC; Feng A; Berk DR
Am J Clin Dermatol; 2023 Mar; 24(2):305-313. PubMed ID: 36370336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
